Clinical Studies

Naturally occurring cancers in dogs have been as used as models for human cancers for many reasons; however, the genomic profiles of many of these cancers are still incompletely understood. Further definition of these genomic landscapes will allow for improved development of novel diagnostics and therapeutics to diagnose and treat these cancers. The objective of this

Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second

This study may provide information on a multi-drug treatment protocol that may result in improved outcomes for dogs with multicentric lymphoma.

This study will evaluate whether or not a small biopsy from a mast cell tumor is accurate for prognostication purposes.

This study is looking to evaluate the pharmacology profile of CBD in dogs (i.e. how it’s processed in the body) as well as its effectiveness in treating pain in dogs with chronic osteoarthritis. This study will hopefully result in similar studies being conducted in the fields of Neurology and Oncology.

This study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.

We are investigating a new diet that may potentially improve glycemic control in dogs with moderately controlled diabetes.

We are investigating a new diet that may potentially induce insulin remission in cats with newly diagnosed diabetes.

This study aims to evaluate changes in a specific blood hormone that has previously been related to sepsis diagnosis in canine patients surgically treated for sepsis in the abdomen and in healthy dogs with intestinal obstructions that are being surgically removed. We are investigating possible novel markers for sepsis with the goal of developing new diagnostic tests.

This trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).

Single Day Clinic: March 7, 2020.

Ethos Discovery is pursuing an investigation into the use of a novel therapy for NME in pugs. This study will only consist of a one-time visit for the blood sample collection. Participating pugs will get free wellness and neurological exams, general bloodwork, and NME-risk factor screening.

This study seeks to understand the intestinal absorption potential of a novel formulation of rapamycin when administered to dogs with naturally occurring cancer. The data from this study will be used to define an ideal dose of the drug to use in future cancer clinical studies.